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Abstract
Background: Obesity increases the risk for development of cardiomyopathy in the absence of hypertension,
diabetes or myocardial ischemia. Not all obese individuals, however, progress to heart failure. Indeed, obesity may
provide protection from cardiovascular mortality in some populations. The fatty acid milieu, modulated by diet,
may modify obesity-induced myocardial structure and function, lending partial explanation for the array of
cardiomyopathic phenotypy in obese individuals.
Methods: Adult male Sprague-Dawley rats were fed 1 of the following 4 diets for 32 weeks: control (CON); 50%
saturated fat (SAT); 40% saturated fat + 10% linoleic acid (SAT+LA); 40% saturated fat + 10% a-linolenic acid (SAT
+ALA). Serum leptin, insulin, glucose, free fatty acids and triglycerides were quantitated. In vivo cardiovascular
outcomes included blood pressure, heart rate and echocardiographic measurements of structure and function. The
rats were sacrificed and myocardium was processed for fatty acid analysis (TLC-GC), and evaluation of potential
modifiers of myocardial structure including collagen (Masson’s trichrome, hydroxyproline quantitation), lipid (Oil
Red O, triglyceride quantitation) and myocyte cross sectional area.
Results: Rats fed SAT+LA and SAT+ALA diets had greater cranial LV wall thickness compared to rats fed CON and
SAT diets, in the absence of hypertension or apparent insulin resistance. Treatment was not associated with
changes in myocardial function. Myocardial collagen and triglycerides were similar among treatment groups;
however, rats fed the high-fat diets, regardless of composition, demonstrated increased myocyte cross sectional
area.
Conclusions: Under conditions of high-fat feeding, replacement of 10% saturated fat with either LA or ALA is
associated with thickening of the cranial LV wall, but without concomitant functional changes. Increased myocyte
size appears to be a more likely contributor to early LV thickening in response to high-fat feeding. These findings
suggest that myocyte hypertrophy may be an early change leading to gross LV hypertrophy in the hearts of
“healthy” obese rats, in the absence of hypertension, diabetes and myocardial ischemia.
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Background
In the United States the prevalence of overweight and
o b e s ea d u l t sa v e r a g e s2 6 %nationally,[1] having
increased nearly 20% over the last 3 decades[2]. Beyond
the human toll lies the economic cost that is projected
to be 900 billion by the year 2030[3]. Obese individuals
have a higher risk of morbidity and mortality attributed
to cardiovascular disease,[4] and specifically are at
higher risk for the development of cardiomyopathy lead-
ing to heart failure[5,6]. Obesity-mediated cardiomyopa-
thy (OC) and heart failure have traditionally been
attributed to hypertension, myocardial ischemia and dia-
betes. More recently, increased left ventricular (LV)
mass and myocardial dysfunction have been associated
with obesity in otherwise healthy humans (i.e. without
concomitant hypertension, ischemic heart disease or
apparent insulin resistance)[7-11]. Left ventricular
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that reflects increased LV mass. This structural change
is commonly identified in obese individuals,[12] and LV
mass has been positively associated with adiposity and
body mass index[11,13,14]. Importantly, LVH is an inde-
pendent risk factor for development of systolic dysfunc-
tion,[15] and is associated with an increased risk for
cardiovascular and all-cause mortality in people[16-18].
It is unknown why some obese individuals progress to
heart failure, while others appear to be protected from
mortality[19]. It is possible that diet composition is one
factor that predicts the cardiac phenotype in response to
obesity, and therefore disease progression. There is evi-
dence that the fatty acid milieu predicts structural and
functional changes in the heart that occur with obesity.
Saturated and n-6 polyunsaturated fatty acids (PUFA)
enhance myocyte apoptosis and necrosis,[20,21] while
monounsaturated and n-3 PUFA attenuate apoptosis in
cardiac and endothelial cells[22,23]. In addition, feeding
of n-6 PUFA to normal pigs was associated with myo-
cardial inflammation, while feeding
n-3 PUFA was associated with anti-inflammatory
effects[24]. Further, dietary fat composition may differ-
entially impact LV structure and contractile function,
[25,26] and studies of cultured myocytes support this
idea[27].
Collectively, these findings suggest that LVH may be
an important early event in the development of myocar-
dial dysfunction in obese individuals. At the cellular
level, a thickened LV may be attributed to extracellular
matrix (ECM) remodeling, myocardial lipid accumula-
tion and/or cardiac myocyte hypertrophy. There is evi-
dence that these processes are differentially expressed
according to dietary fat, so were chosen for emphasis in
the present study. The human population more fre-
quently experiences obesity as a result of nutritional and
lifestyle factors compared to genetic aberrancy; thus, a
dietary obese model was chosen for this study. We pro-
pose that defining alterations in cardiac structure and
function attributable to obesity may be best accom-
plished by investigating the effects of combined fatty
acid moieties from a dietary source, in the in vivo set-
ting of intact anti-inflammatory and antioxidant systems.
The purpose of this study was to determine whether
the heterogeneous phenotype of OC might be partially
attributed to dietary fatty acid composition. Primary
outcomes included myocardial structure and function,
measured echocardiographically, in addition to ECM
remodeling, myocardial lipid accumulation and cardiac
myocyte hypertrophy. To understand the morphologic
and metabolic milieu within which primary outcomes
were measured, we secondarily characterized adiposity,
hemodynamics, serum metabolic indices and myocardial
fatty acid composition.
We hypothesized that long-term feeding of a high
saturated fat diet would be associated with LVH, and
that concomitant intake of n-6 PUFA and n-3 PUFA
would exacerbate and attenuate, respectively, this early
structural change. Further, we hypothesized that despite
the presence of LVH, myocardial function, measured
echocardiographically, would remain intact in these diet-
ary obese rats. Regarding contributors to LV thickening,
it was anticipated that intake of a diet high in saturated
fat and n-6 PUFA would result in the most profound
lesion severity, compared with other high fat diets
tested.
Methods
Animals
Adult male Sprague-Dawley (SD) rats (CD
® IGS Rat,
Charles River Laboratories, Wilmington, MA) were
maintained in the Colorado State University Laboratory
Animal Resource Center in a temperature- and humid-
ity-controlled environment. Rats were housed in pairs
with a normal 12-hour light/12 hour dark cycle. Proto-
cols and conditions within the facility meet or exceed
the standards for animal housing facilities as described
in the Animal Welfare Act regulations, the Guide for
the Care and Use of Laboratory Animals and the Guide
for the Care and Use of Agricultural Animals in Agri-
cultural Research and Teaching. The rats were allowed a
2-week acclimation period prior to initiation of dietary
treatment.
Diet At 6 weeks of age, rats were divided into 1 of 4
dietary treatment groups: control (CON); 50% saturated
fat (SAT); 40% saturated fat + 10% n-6 PUFA composed
primarily of linoleic acid (LA) (SAT+LA) and 40% satu-
r a t e df a t+1 0 %n - 3P U F Ac o m p o s e dp r i m a r i l yo fa-
linolenic acid (ALA) (SAT+ALA). Diets were supplied
by Harlan Teklad (Madison, WI), and are detailed in
Tables 1 and 2. The duration of dietary treatment was
32 weeks. Body weight was measured weekly. Rats were
fasted overnight prior to terminal sample collection.
Table 1 Macronutrient composition and caloric density of
diets
CON SAT SAT+LA SAT+ALA
Protein % kcal 20 20 20 20
Carbohydrate % kcal 69 28 28 28
Fat % kcal 11 52 52 52
Saturated fat % total FA 43 93 79 79
Monounsaturated fat % total FA 84 4 4
Polyunsaturated fat % total FA 49 3 16 16
Kcal/g 3.6 4.5 4.5 4.5
CON, Control; SAT, 50% saturated fat; SAT+LA, 40% saturated fat + 10% n-6
PUFA; SAT + ALA, 40% saturated fat + 10% n-3 PUFA.
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G e n e r a la n e s t h e s i aw a si n d u c e db yp l a c i n gr a t si na
commercial rodent anesthesia chamber and initiating
flow of 3% isofluorane in a 95% O2/5% CO2 gas mixture.
Anesthesia was maintained by nosecone at 2% isofluor-
ane for noninvasive measurements, and at 4% isofluor-
ane for terminal sample collection.
Serum measurements
Serum leptin, glucose and free fatty acid (FFA) concen-
trations were measured in the University of Colorado
Hospital Clinical and Translational Research Center.
Leptin was measured using the Rat Leptin Radioimmu-
noassay Kit (Millipore, St. Charles, MO). Glucose and
FFA were quantitated using the Roche Cobas Mira Plus
Chemistry Analyzer (Indianapolis, IN). Insulin was
quantitated by a commercial rat insulin ELISA (Linco
Research, St. Charles, MO). The Homeostasis Model
Assessment (HOMA) was used to estimate insulin resis-
tance using a HOMA2 IR Excel-based calculator (http://
www.dtu.ox.ac.uk/homacalculator/download.php). Serum
triglycerides (TG) were assayed using enzymatic colori-
metry (Triglycerides Reagent, Thermo Electron, Pitts-
burg, PA).
Systolic blood pressure and heart rate
Immediately upon moving to the maintenance dose of
2% isofluorane, rats were moved to a temperature con-
trolled platform for determination of heart rate (HR)
and systolic blood pressure by the tail cuff method (SC
1000 Pressure Analysis System, Hatteras Instruments,
Cary, NC). Three separate measurements of both HR
and systolic blood pressure were recorded.
Echocardiographic examination
After HR and blood pressure determination, rats were
shaved over the ventral thorax and upper abdomen. A
Philips HD-11 ultrasound machine with a 12 mHz
pediatric sector transducer was used to image the heart
in transverse parasternal and 4-chamber views. Two
dimensional, M-mode and Doppler imaging was incor-
porated to measure LV end-diastolic and end-systolic
wall and chamber dimensions and isovolumic relaxation
time (IVRT), an index of diastolic function. Left ventri-
cular mass was estimated using a formula adapted from
Foppa et al:[28]
LV mass : 0.8 (1.04([LVIDd +L V W cr/d +L V W ca/d]3 − [LVIDd]3)) + 0.6 g
where LVIDd = LV internal diameter during diastole,
LVWcr/d = cranial LV wall thickness during diastole and
LVWca/d = caudal LV wall thickness during diastole.
Dual Energy X-Ray Absorptiometry (DEXA) Scans
were performed on anesthetized rats at the Colorado
State University Veterinary Medical Center using a Del-
phi A densitometer (Hologic, Inc., Bedford, MA).
Processing of tissue samples
The heart was exposed through a medial sternotomy.
Blood was aspirated from the pulmonary arterial trunk
and immediately placed into a collection tube. After 2
hours, the blood was centrifuged at 2095 RCF for 15
minutes. After centrifugation, serum was aspirated and
stored at -80°C.
Immediately upon withdraw of the blood sample, the
heart was excised and placed in ice cold saline, then
quickly dabbed for excess fluid prior to recording of
heart weight. While in the iced saline, the heart was dis-
sected to isolate the LV, right ventricle and septum, and
isolated tissue weights were recorded. Samples of right
and left ventricular and septal myocardium were divided
and either snap frozen in liquid nitrogen and stored at
-80°C or fixed in 4% paraformaldehyde. After 24 hours
in paraformaldehyde, tissues were transferred to 70%
ethanol, then trimmed and embedded in paraffin. The
mass of visceral adipose was estimated by removing and
weighing the mesenteric fat.
Collagen
Masson’s trichrome stain was used for collagen detec-
tion in paraffin-embedded tissue sections. A slide from
each animal was evaluated at 20X for regions of trans-
versely sectioned cells without artifact or large vessels.
Four images per slide, comprising identical total areas
among slides, were assessed for % total area that was
positive for Masson’s staining, using NIH Image J soft-
ware. Hydroxyproline (a primary amino acid in collagen)
Table 2 Fatty acid composition of diets (% of total diet)
CON SAT SAT+LA SAT+ALA
8:0 0.14 2.03 1.80 1.80
10:0 0.09 1.35 1.20 1.20
12:0 0.72 10.8 9.60 9.60
14:0 0.24 3.60 3.20 3.20
16:0 0.28 2.51 2.10 1.98
18:0 0.24 3.59 2.58 2.58
18:1 n-9 0.33 1.01 1.04 0.96
18:2 (LA) 1.95 0.85 4.06 3.11
18:3 (ALA) 0.00 0.00 0.20 1.38
n-6 1.95 0.85 4.06 3.11
n-3 0.00 0.00 0.20 1.38
n-6:n-3 N/A N/A 20.3:1 2.26:1
LA, Linoleic acid; ALA, a-linolenic acid; N/A, not applicable; CON, Control; SAT,
50% saturated fat; SAT+LA, 40% saturated fat + 10% n-6 PUFA; SAT + ALA,
40% saturated fat + 10% n-3 PUFA.
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trically using previously described methods[29].
Lipid analysis
Oil Red O staining was applied to myocardial cryostat
sections. Septal TG were extracted and quantitated
using a commercial colorimetric Triglyceride Quantifi-
cation Kit (BioVision Research Products, Mountain
View, CA).
Lipids were extracted from frozen septal tissue using
the method described by Matyash et al.[30] Briefly,
0.05 gm tissue samples were pulverized into a powder
under liquid nitrogen and placed in a glass homogeni-
zer. Mass spectrometry (MS) grade methanol (0.75
mL) and methyl-tert-butyl ether (MTBE, 2.5 mL) were
added and the powdered tissue was homogenized
briefly on ice. Samples were capped off under nitrogen
gas and incubated at room temperature for one hour,
then 0.625 mL of MS grade water was added. After
vortexing, samples were capped off under nitrogen and
incubated at room temperature for an additional 10
minutes, then centrifuged at 1,000 RCF for 10 minutes.
The upper (organic) phase was collected and the sam-
ple dried under a stream of nitrogen. Samples were
frozen at -80°C until processed. Thin layer chromato-
graphy (TLC) was then used to separate out the phos-
pholipid fraction using a 20 cm × 20 cm silica gel TLC
plate in a 70:30:1 hexane:ethyl ether:acetic acid solu-
tion. The band associated with the phospholipid frac-
tion was scraped from the plate and dissolved in 0.5
ml hexane and 0.5 ml 0.5N KOH. Three ml of 14%
BF3-methanol was added and each sample was placed
on a heat plate at 70 °C for 1.5 hours to obtain methyl
esters in preparation for gas chromatography (GC).
The GC analysis was performed using an Agilent 6890
Series Gas Chromatographer (Agilent Technologies,
Inc., Santa Clara, CA). The column used was an Agi-
lent Technologies DB-225 30 m × 0.250 mm × 0.25
μm, model 122-2232. The initial temperature of the
oven was 100 °C with an initial ramp temperature of
10°C/min for 10 minutes, then 2.5°C/min for 4 min-
utes and held at 210°C for the remaining 15 minutes
for a total run time of 29 minutes. The inlet split ratio
was 20:1 with the column at constant flow and an
initial flow, pressure and velocity at 2.0 ml/min, 23.86
psi and 44 cm/sec, respectively.
Myocyte cross sectional area
Sections of LV were stained with hematoxylin and eosin,
and cross sectional area was measured using NIH Image
J software. Fifty transversely sectioned cells with central
nuclei from each of 2 slides per rat were evaluated (i.e.
100 cells/rat). In 5/22 rats, only 50 cells/rat met stan-
dards for measurement.
Statistics
Initial analyses were conducted using Prism 4.0 for
Macintosh (Graphpad Software, Inc., San Diego, CA)
and SPSS version 19 (IBM,S o m e r s ,N Y ) .B a r t l e t t ’st e s t
f o re q u a l i t yo fv a r i a n c ea n dt h eK o l m o g o r o v - S m i r n o v
test for Gaussian distribution were applied to all data-
sets. The Kruskal-Wallis nonparametric test and Dunn’s
post test were used to analyze non-normal data. Pear-
son’s and Spearman’sc o r r e l a t i o n sw e r ea p p l i e dt on o r -
mal and non-normal data, respectively. Treatment
groups were compared using 1-way ANOVA. When the
overall ANOVA F-test p-value was < 0.05, the LSD
method for pairwise comparisons was used. Because
regional wall thickness during systole and diastole were
likely to be highly correlated, multivariate analysis of
variance (MANOVA) was used to analyze echocardio-
graphic LV wall thickness variables as a set, prior to
analysis of the individual wall thickness variables. Com-
putations were performed using the GLM procedure in
SAS software (SAS Institute Inc., Cary, NC) version 9.2.
Significance was determined by inspecting the 4 multi-
variate tests provided. Data are expressed as mean +/-
SE; statistical significance was set at p < 0.05.
Results
Data relevant to body morphometry, organ weights,
hemodynamics and serum metabolic indices are pre-
sented in Table 3. Rats fed diets supplemented with
PUFA, whether LA or ALA, had higher body weights
than CON rats; further, SAT + ALA rats had higher
body weights compared to SAT rats. There were no dif-
ferences in % body fat by DEXA or in postmortem visc-
eral adipose mass; however, visceral adipose mass was
correlated with body weight (r = 0.69, p < 0.0001).
Heart weight and LV weight were similar among groups.
Treatment did not alter HR or systolic blood pressure.
Serum metabolic indices were unchanged by diet; how-
ever, leptin was correlated with % body fat (r = 0.86, p <
0.0001) and visceral adipose mass (r = 0.78, p < 0.0001).
Myocardial fatty acid profiles are presented in Table 4.
With the exception of palmitic and oleic acids, the tis-
sue composition generally reflected direct dietary intake
or intake of precursors.
Myocardial outcomes are listed in Table 5. Multivari-
ate analysis of cranial wall dimensions during systole
and diastole revealed significant differences in cranial
wall measurements based on all 4 multivariate tests (p =
0.009-0.038). The 1-way ANOVA tests of systole and
diastole separately revealed that cranial LV wall thick-
ness was increased in rats from both PUFA-supplemen-
ted groups compared to CON animals. Moreover, rats
fed both SAT + LA and SAT + ALA diets had increased
cranial wall thickness during diastole compared to rats
fed the SAT diet, and rats fed the SAT + LA diet also
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pared to rats fed the SAT diet. Correlations between
cranial LV wall thickness measurements and % body fat
by DEXA or visceral adipose weight were weak to non-
existent (Table 6). Caudal LV wall measurements during
systole and diastole were not different based on MAN-
OVA (p = 0.164-0.372). Left ventricular mass, estimated
from echocardiographic data and indexed to body
weight, was similar among groups. This estimate of LV
mass correlated to body weight and visceral adipose
mass, but not to overall adiposity as measured by DEXA
(Table 6). Systolic and diastolic functional indices (i.e.
fractional shortening and IVRT, respectively) were not
different between groups. Dietary treatment did not
alter myocardial TG or collagen content. Oil Red O
staining was negligible across treatment groups (data
not shown). Cardiac myocyte cross sectional area was
i n c r e a s e di na l lf a t - f e dg r o u p sc o m p a r e dt oc o n t r o l ;
however, there was no difference in area between the
fat-fed groups. There was no correlation between body
weight or visceral adipose mass, and measures of TG,
hydroxyproline or myocyte area.
Conclusions
The aim of this study was to develop insights into the
heterogeneity of OC. Accordingly, we sought to identify
a profile of related gross and cellular myocardial pro-
cesses that may be specific to dietary fatty acid composi-
tion, using dietary obese SD rats. This study revealed
diet-specific changes in myocardial fatty acid composi-
tion, LV thickening and myocyte hypertrophy without
associated changes in myocardial function.
Morphometric, hemodynamic and metabolic profiles
In the present study, only the PUFA-fed rats had
increased body weight compared to control animals,
and a difference associated with dietary fat composi-
tion was demonstrated in that SAT + ALA-fed rats
had greater body weights than rats fed the SAT diet
alone. Increased visceral adipose mass (or “visceral
adiposity”), compared to increased body weight, is a
stronger risk factor for the development of LVH, OC
and failure[31-33]. Both the fatty acid composition[34]
and mass[32,35] of the visceral adipose determine the
potential for this depot to secrete factors that are
believed to contribute to OC[32,36-38]. The present
study revealed only a trend toward increased body fat
and visceral adipose mass in fat-fed rats. Though dif-
ferences in primary myocardial outcomes must be
interpreted in the absence of significant treatment dif-
ferences in adipose mass, it is possible that the secre-
tory profile of the visceral adipose was altered
according to dietary influence on fatty acid composi-
tion and gene expression[39-41].
Table 3 Data summary including body morphometry,
tissue masses, hemodynamics and serum metabolic
indices
CON SAT SAT+LA SAT
+ALA
p
Body morphometry and tissue mass
Body wt (gm) 550/11.6 571/12.1 616/12.4* 625/
26.7**
#
0.024
% body fat (DEXA) 20.1/2.58 26.8/2.20 25.5/2.80 26.4/1.78 0.199
Visceral adipose wt
(gm)
4.37/.701 6.03/.769 7.23/1.35 7.21/.811 0.145
Visceral adipose:
body wt
.008/.001 .011/.001 .012/.002 .011/.001 0.248
Heart wt:body wt .003/
.0002
.003/
8.869
e-005
.003/
6.234
e-005
.003/
4.871
e-005
0.365
Heart wt:brain wt .804/.037 .798/.022 .833/.018 .845/.033 0.593
LV wt:body wt .0017/
.0001
.0015/
6.684
e-005
.0014/
3.233
e-005
.0014/
8.451
e-005
0.102
Heart rate and blood pressure
HR (bpm) 358/7.66 357/11.0 390/10.4 350/6.91 0.090
SPB (mm Hg) 141/9.08 163/9.81 157/11.3 146/3.87 0.272
Serum measurements and HOMA
Leptin (ng/mL) 4.55/1.34 6.71/1.20 7.42/1.96 7.28/
0.811
0.438
Insulin (pmol/L) 93.3/11.1 61.5/9.83 82.6/9.09 79.0/9.32 0.259
Glucose (mg/dl) 167/13.0 176/12.1 183/15.2 177/8.74 0.740
FFA (uEq/L) 509/56.3 441/45.9 434/32.2 386/13.7 0.188
TG (mmol) .620/.091 .612/.066 .560/.087 .573/.049 0.893
HOMA 5.61/1.29 4.43/.657 5.08/.503 4.74/.512 0.875
Data listed as mean/SE. CON, Control; SAT, 50% saturated fat; SAT+LA, 40%
saturated fat + 10% n-6 PUFA; SAT + ALA, 40% saturated fat + 10% n-3 PUFA.
*p < 0.05 compared to control; **p < 0.01 compared to control; #p < 0.05
compared to SAT.
Table 4 Fatty acid profile of myocardial phospholipid
fractions
CON SAT SAT+PUFA6 SAT+PUFA3 p
16:0 10.40/.1632 7.67/.1118** 8.13/.1026 8.85/.1426 0.003
18:0 20.94/.0486 25.96/.1592** 25.21/.1392 24.47/.1712 0.003
18:1 8.10/.3686 7.40/.2512 4.24/.1463* 4.43/.1312 0.009
18:2 18.96/.8193 14.25/.3933 18.96/.4124 18.62/.7574 0.035
18:3 .1361/.0251 .1269/.0050 .0715/.0026 .4635/.0190
++ 0.010
20:4 26.15/.6430 29.85/.3703 24.22/.4919 19.13/.3994
## 0.004
22:5 .4004/.0321 .3316/.0341 1.711/.1507 4.754/.1906
## 0.004
22:6 2.416/.1158 2.910/.0752 8.557/.2385 14.27/1.387** 0.003
23:1 6.21/.705 5.50/.699 3.03/.426 0/0**
# 0.004
Data listed as mean/SE. CON, Control; SAT, 50% saturated fat; SAT+LA, 40%
saturated fat + 10% n-6 PUFA; SAT + ALA, 40% saturated fat + 10% n-3 PUFA.
*p < 0.05 compared to control; **p < 0.01 compared to control; #p < 0.05
compared to SAT;
## p < 0.01 compared to SAT; ++ p < 0.01 compared to SAT+PUFA6.
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did not modify systolic blood pressure or HR, suggest-
ing that primary outcomes may be interpreted in the
absence of increased afterload. Similarly, serum glu-
cose, serum insulin and calculated HOMA were
unchanged by dietary treatment. Though fasting con-
centrations and subsequent HOMA calculations offer
only gross approximations of insulin sensitivity, these
findings indicate that neither hyperglycemia nor hyper-
insulinemia are likely to be key factors influencing pri-
mary outcomes.
Myocardial fatty acid composition
Dietary fatty acids determine the fatty acid composi-
tion of the myocardium, and changes in the type of
myocellular lipids are associated with altered intracel-
lular signaling, including pathways that may be impor-
tant in modulating myocyte metabolism, hypertrophy,
contractile function and ultimately survival[42-46].
Overall, comparisons of tissue fatty acid profiles
between studies must be made cautiously due to var-
iance in diets and lipid fractions studied. Further, the
complex interplay of dietary fatty acids and rates of
uptake, oxidation and metabolism is beyond the scope
of this paper. With these limitations in mind, the fatty
acid composition of the total phospholipid fraction in
CON rats was similar to that described in another
study of SD rats,[47] with the exception of less myo-
cardial DHA in this study, likely attributable to differ-
ences in dietary content. The data support the idea
that stearic acid (18:0) is more readily incorporated
into the myocardial phospholipid fraction compared to
palmitic (16:0) and oleic (18:1) acids,[48] and that
increased available LA (18:2) may be preferentially
incorporated, resulting in displacement of oleic and
palmitic acids. The observed increase in myocardial
DHA[49,50] and decrease in arachidonic acid (AA
20:4) [49-51] with ALA feeding have been reported
previously.
Table 5 Summary of echocardiographic measurements, myocardial hydroxyproline and triglyceride content and
myocyte area
CON SAT SAT+LA SAT+ALA p
Echocardiographic measurements
LVWcr/s (cm) .309/.008 .329/.009 .371/.018**
# .355/.012* 0.013
LVWcr/d (cm) .203/.005 .201/.003 .230/.010*
# .227/.008*
# 0.021
LVWca/s (cm) .289/.013 .315/.016 .327/.016 .300/.010 0.272
LVWca/d (cm) .185/.012 .198/.008 .201/.013 .206/.011 0.633
LVIDd (cm) .824/.027 .799/.009 .798/.018 .809/.030 0.868
LVIDs (cm) .501/.026 .456/.018 .418/.034 .473/.028 0.234
LV mass:body wt .0029/.0001 .0028/8.950
e-005
.0028/7.855
e-005
.0028/8.966
e-005
0.695
IVRT (sec) .026/.001 .029/ < .001 .027/ < .001 .027/ < .001 0.265
FS (%) 39.3/1.54 42.9/2.00 47.8/3.47 41.7/1.91 0.112
Myocardial collagen and triglyceride; myocyte area
Hydroxyproline (ug/mg dry wt)
n = 4-6
.753/.261 .555/.112 .638/.128 .661/.117 0.837
Triglyceride (nMol/gm wet wt)
n = 3-6
9.47/3.67 12.4/1.88 9.11/2.12 9.28/1.21 0.676
Collagen (%)
n = 5-6
.055/.004 .053/.005 .045/.003 .044/.004 0.254
Myocyte cross sectional area (microns
2)
n = 5-6
492/30.5 628/23.2** 602/25.1* 610/33.8* < 0.018
Data listed as mean/SE. LVW, left ventricular wall; LVID, left ventricular internal diameter; IVRT, isovolumic relaxation time; FS, fractional shortening; cr, cranial; ca,
caudal; s, systole; d, diastole; CON, Control; SAT, 50% saturated fat; SAT+LA, 40% saturated fat + 10% n-6 PUFA; SAT + ALA, 40% saturated fat + 10% n-3 PUFA.
*p < 0.05 compared to control; **p < 0.01 compared to control; #p < 0.05 compared to SAT.
Table 6 Summary of correlation data comparing key
myocardial outcomes to adiposity and body weight
Correlation r p
LVWcr/s and % body fat (DEXA) 0.23 0.309
LVWcr/s and visceral adipose wt 0.42 0.058
LVWcr/s and body wt 0.47 0.031
LVWcr/d and % body fat (DEXA) 0.08 0.722
LVWcr/d and visceral adipose wt 0.47 0.034
LVWcr/d and body wt 0.45 0.042
LV mass and % body fat (DEXA) 0.21 0.361
LV mass and visceral adipose wt 0.51 0.017
LV mass and body wt 0.67 < 0.001
LVW, left ventricular wall; cr, cranial; ca, caudal; s, systole; d, diastole.
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Effects of dietary fats on myocardial structure and func-
tion in the setting of pressure overload have been
demonstrated[52-54]. Less is known about the role of
dietary fatty acid composition in OC, without concomi-
tant hypertension, myocardial ischemia or diabetes. In
the present study, LV thickening was associated with
PUFA feeding (SAT + LA and SAT + ALA groups) in
the absence of hyperglycemia, hyperinsulinemia or
hypertension. The effect of high-fat diet composition
was demonstrated in that PUFA-fed rats had greater
thickening than rats fed the SAT diet. The LV thicken-
ing in PUFA-fed rats was regional; the cranial (anterior)
wall, but not the caudal (posterior) wall, was affected.
These data, combined with poor or nonexistent correla-
tion of cranial LV thickness with adiposity and body
weight, suggest that diet may be more important than
morphometry in the development of focal LV thicken-
i n g .H e a r ta n dL Vm a s s e sw e r en o td i f f e r e n ta m o n g
treatment groups, suggesting either focal areas of thick-
ening that did not contribute remarkably to overall mass
in PUFA-fed rats, or replacement of normal parenchyma
with a matrix of lesser density. Unchanged myocardial
TG and hydroxyproline content (discussed below) sup-
ports the former idea. Correlative data suggest that in
contrast to measures of focal LV thickening, total LV
mass may be better predicted by visceral adipose mass
and body weight than by diet. The LV thickening pre-
sent in PUFA-fed rats was not associated with in vivo
systolic or diastolic dysfunction measured echocardio-
graphically. These findings are consistent with those in
human studies describing increased LV mass without
concomitant dysfunction in obese individuals[55]. Com-
paring these data with those from other rodent studies,
increased heart weight and impaired function, as mea-
sured in isolated papillary muscles and myocytes, were
reported in rats in response to short-term high-fat feed-
ing[56,57]. In contrast, in vivo studies using echocardio-
graphy have revealed no change in myocardial structure
and function in response to 8 weeks of high SAT and
PUFA feeding,[58] but others observed increased LV
mass and impaired contractile function in mice fed a
high fat diet for 20 weeks[59]. It is likely that chronicity,
distribution and underlying etiology of LVH combine to
determine subsequent function.
Though it is not uncommon for LVH to exist in the
absence of measureable functional change, some factors
should be considered relevant to the present study. It is
possible that more sensitive echocardiographic indica-
tors of myocardial function, such as tissue Doppler ima-
ging and related methods,[10] may reveal early and
subtle functional changes attributed to dietary obesity
that are not measureable with conventional echocardio-
graphic techniques used in the majority of studies to
date. Additionally, it is possible that despite normal sys-
tolic and diastolic function at rest, conditions of
increased workload or myocardial stress would reveal
impaired function[56]. Regarding dietary treatment cho-
sen for this study, it is possible that any beneficial
effects of n-3 supplementation were obscured by conco-
mitant feeding of high saturated fat[60]. It should also
be considered that dietary simple carbohydrates, rather
than fatty acid composition, play a prominent role in
promoting the cardiomyopathic phenotype. Short term
effects of a high-fat, high-simple carbohydrate diet were
demonstrated in dietary obese Wistar rats that devel-
oped myocardial hypertrophy and impaired systolic and
diastolic function with just 16 weeks of dietary treat-
ment[61,62]. Finally, it is acknowledged that a limitation
of this study that precludes definitive correlation of
myocardial composition with function was the use of
interventricular septal tissue for measurement of myo-
cardial fatty acids, hydroxyproline and TG, given that
gross structure and function were measured in the cra-
nial and caudal LV free walls. Regional differences in
myocardial protein expression,[63] substrate uptake[64]
and hypertrophy[10] have been demonstrated. It is
therefore not valid to assume that changes in the sep-
tum wholly reflect those observed in the LV free wall.
With these considerations in mind, it would be erro-
neous to conclude that diet-induced changes in myo-
cardial fatty acid composition are unassociated with
functional impairment. It is widely appreciated that
dietary n-3 PUFA are protective against cardiomyopa-
thy,[65,66] and that diets enriched in n-6 PUFA are
associated with exacerbation of processes relevant to
cardiomyopathy and heart failure[24,67]. It is likely
that changes in oxidative stress and inflammation, as
well as aberrant myocyte metabolism, were present but
not manifest as resting dysfunction detectable
echocardiographically.
Myocyte cross sectional area
Regarding the potential contributors to LVH, namely
myocyte hypertrophy, ECM remodeling and lipid accu-
mulation, this study showed that myocyte cross sectional
area was increased with feeding of all high-fat diets,
regardless of composition. These observations are con-
sistent with those of obese humans. Right heart endo-
cardial biopsies obtained from markedly obese patients
with heart failure, mostly attributed to dilative cardio-
myopathy, revealed that the most common histologic
lesion was mild myocyte hypertrophy that was not
described as causative, present in 67% of obese subjects
[68]. Evidence of myocyte hypertrophy was also the pre-
dominant finding in hearts of obese individuals without
premortem evidence of heart disease[12]. This, along
with our finding that myocyte hypertrophy did not
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cyte hypertrophy is the most consistently identified
myocardial lesion in obese individuals, its presence is
not likely to solely contribute to clinically relevant LVH.
Hypertrophic stimuli, and subsequent genotypic and
phenotypic responses, are very diverse[69,70]. Certainly
am e a s u r eo fc r o s ss e c t i o n a la r e ao n l yd e f i n e st h ep r e -
sence of the phenomenon, and it is likely that myocyte
gene expression, signaling pathways and subsequent pre-
servation or deterioration of structure and function are
different according to fatty acid milieu,[71] degree of
adiposity, adipokine profile[72] and metabolic aberrancy.
Myocardial extracellular matrix remodeling
In addition to myocyte hypertrophy, this study investi-
gated ECM remodeling and lipid accumulation as poten-
tial contributors to LVH. ECM remodeling is present in
failing hearts regardless of etiology,[73] and it is well
documented that altered ECM composition contributes
to myocardial pathology. Fibrosis, however, is not uni-
formly present in hypertrophic hearts of obese indivi-
duals[12]. In the present study, long-term high fat
feeding was not associated with increased myocardial
collagen. These data are consistent with short-term stu-
dies that measured unchanged interstitial collagen in
response to moderate- and high-fat feeding[74,75]. In
contrast, other studies revealed that Wistar rats fed
either a high-fat or high-fat, high-simple carbohydrate
diet for ≈16 weeks had increased myocardial collagen
staining[61,62,76]. In addition to diet composition,
serum leptin concentrations may impact myocardial
ECM homeostasis. In cultured cardiac myocytes, leptin
increased collagen expression and matrix metalloprotei-
nase activity[77]. The absence of hyperleptinemia in the
rats of the present study may lend partial explanation
for ECM preservation.
Myocardial lipid accumulation
There is disparate evidence regarding the occurrence
and relevance of TG (i.e. neutral lipid) accumulation in
obesity. Evidence suggests that overweight and obese
individuals have increased myocardial TG deposition
compared to lean subjects[78,79]. In contrast, LV tissue
from humans with end-stage nonischemic heart failure
revealed no difference in intramyocardial lipid staining
in hearts from lean and obese subjects[79]. Further,
postmortem examination of 12 obese individuals with-
out evidence of hypertension or myocardial ischemia
identified only scant fatty infiltration in 3 of the subjects
[12]. Regarding functional relevance, greater myocardial
lipid has been linked with LVH and systolic dysfunction,
[78,80] while reduced myocardial lipid was associated
with attenuated apoptosis and fibrosis[81]. In contrast,
other work suggests that TG accumulation may be
protective when alternative pathways lead to formation
of harmful bioactive products. Study of cultured cells
showed that incubation with oleic acid drives accumula-
tion as TG and preserves cell viability, while exposure to
palmitic acid leads to ceramide accumulation and apop-
tosis[82]. Rodent high-fat feeding studies reveal both
increased [56,83] and unchanged myocardial TG[84].
Findings of the present study are consistent with the lat-
ter, and expand the observation to include high-fat diets
of variable fatty acid composition. Given the trend
toward increased TG content in rats fed the SAT diet,
however, additional work is warranted to determine
whether this observation may represent a diet-specific
effect.
Strain and model considerations
When possible, the above discussion has focused on
models of OC without concomitant genetic anomalies
or induced pathology (i.e. aortic banding, spontaneous
hypertension). Within these studies, the data collectively
suggest that there may be strain differences and variabil-
ity in whole animal vs. ex vivo outcomes. Regarding
strain, Wistar and SD rats have distinct lipid metabo-
lism,[85] and Wistars may develop myocardial pathology
with shorter dietary interventions[56,86]. Additional
strain differences in metabolic and myocardial responses
to high-fat feeding have been demonstrated[87,88].
Regarding model type, evidence suggests that ex vivo
studies of OC reveal more profound pathology than
observed in vivo, and this has been partly attributed to
endogenous protective mechanisms[21]. While contrac-
tile dysfunction may have been present in isolated mus-
cles or cells from the rats in this study, overall gross
systolic and diastolic function was seemingly intact. As
noted, there may be distinct signaling pathways that are
specific to predominant dietary fatty acids but result in
overtly similar outcomes. For this reason, it will be
important to subsequently characterize genotype and
major hypertrophic pathways to investigate potential dif-
ferences at the cellular level.
Limitations
Study limitations include the aforementioned use of
interventricular septal tissue for measurement of myo-
cardial fatty acids, hydroxyproline and TG, given that
echocardiographic measurements of structure and
function were derived from images of the cranial and
caudal LV free walls. Additionally, it is likely that
increasing sample size and dividing subjects into obe-
sity-prone and obesity-resistant groups would have
reduced variability within treatment groups and more
clearly elucidated significant differences. Further, echo-
cardiographic assessment under conditions of myocar-
dial stress (i.e. dobutamine administration) may have
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resting conditions used in the present study. Finally,
our understanding of the temporal effects of diet on
outcomes would have been improved by conducting
measurements over time. By doing this, more accurate
comparisons with short-term studies could be made,
and potential homeostatic/compensatory mechanisms
engaged with long-term feeding could be identified.
Conclusions
The findings of this study suggest that, under conditions
of high-fat feeding, replacement of 10% saturated fat
with either LA or ALA is associated with increased body
weight and segmental LV wall thickness in the absence
of myocardial functional changes. Increased myocyte
size, similar among all fat-fed groups, appears to be a
more likely precursor to measureable LV thickening in
uncomplicated dietary obesity than collagen accumula-
tion or lipid accretion; however, increased myocyte size
did not determine gross LV hypertrophy. Predicted
responses to PUFA type were not actualized in the out-
comes measured in the present study; thus, future stu-
dies will measure myocardial gene and protein
expression in response to diet, to determine whether
hypertrophic pathways are differentially regulated and
possibly predictive of a physiologic versus pathologic LV
response. Inclusion of simple carbohydrates as part of a
western diet in rodents should be further investigated as
a relevant model of diet-induced OC in humans, specifi-
cally in relation to LVH as a precursor to functional
decline.
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